SCHEMBL5956746

SCHEMBL5956746

O=C1CCCSc2cc(Br)ccc21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.47
HTT P42858 1/20 0.47
PARP10 Q53GL7 2/20 0.40
VHL P40337 1/20 0.40
ELOC Q15369 1/20 0.40
ELOB Q15370 1/20 0.40
PARP11 Q9NR21 1/20 0.40
ALDH1A1 P00352 3/20 0.39
S100A4 P26447 1/20 0.38
MAOA P21397 3/20 0.38
MAOB P27338 3/20 0.38
METAP1 P53582 1/20 0.38
TDP1 Q9NUW8 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
TDP2 O95551 1/20 0.37
LMNA P02545 1/20 0.36
MAPT P10636 1/20 0.36
MAPK1 P28482 1/20 0.36
PRKCI P41743 1/20 0.35
PTPRC P08575 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13135 0.89 KDM4E (0.58) KDM4EHTTPARP10VHLELOC
SCHEMBL30714352 0.89 KDM4E (0.58) KDM4EHTTPARP10VHLELOC
SCHEMBL5203764 0.86 VHL (0.51) KDM4EHTTPARP10VHLELOC
SCHEMBL23715358 0.79 METAP1 (0.41) KDM4EHTTPARP10PARP11S100A4
SCHEMBL20165295 0.79 MAOA (0.54) KDM4EHTTVHLELOCELOB
SCHEMBL17495034 0.79 CASP1 (0.49) KDM4EHTTVHLELOCELOB
SCHEMBL2594793 0.78 S100A4 (0.43) KDM4EHTTPARP10PARP11S100A4
SCHEMBL29922129 0.78 S100A4 (0.43) KDM4EHTTPARP10PARP11S100A4
SCHEMBL5956877 0.76 KDM4E (0.44) KDM4EHTTVHLELOCELOB
SCHEMBL5956797 0.76 KDM4E (0.44) KDM4EHTTVHLELOCELOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230149414-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-18 US disclosed
US-20230149414-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-18 US disclosed
US-20230149414-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-18 US disclosed
EP-4096657-A1 COMPOUNDS AND USES THEREOF Foghorn Therapeutics Inc. (US) 2022-12-07 EP disclosed
WO-2021155316-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2021-08-05 WO disclosed
WO-2021155316-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2021-08-05 WO disclosed
EP-2750678-B1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS INC (US) 2017-03-22 EP disclosed
WO-2016025932-A1 SUBSTITUTED POLYCYCLIC ANTIBACTERIAL COMPOUNDS PTC THERAPEUTICS, INC. (US) 2016-02-18 WO disclosed
US-20150038438-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. 2015-02-05 US disclosed
EP-1270570-B1 AMIDE COMPOUNDS AND USE THEREOF MITSUBISHI PHARMA CORP (JP) 2006-05-31 EP disclosed
EP-0568898-B1 Benzothiepine-, benzothiopyrane- and benzothiophenyle derivatives, their preparation and use as medicine HOFFMANN LA ROCHE (CH) 1998-04-01 EP disclosed
US-5512683-A OSTEOPOROSIS, IMMUNOSUPPRESSANT HOFFMANN-LA ROCHE INC. (US) 1996-04-30 US disclosed
EP-0350846-B1 Condensed heterocyclic compounds and their use in therapy HOFFMANN LA ROCHE (CH) 1995-10-11 EP disclosed
US-5420273-A Skin disorders and antitumor agents HOFFMAN-LA ROCHE INC. (US) 1995-05-30 US disclosed
US-5391766-A Antiarthritic agents for rheumatoid, immunosuppressants; treating psoriasis, autoimmune diseases HOFFMANN-LA ROCHE INC. (US) 1995-02-21 US disclosed
US-5300522-A Treating inflammatory, allergic, rheumatic, immunological disorders HOFFMANN-LA ROCHE INC. (US) 1994-04-05 US disclosed
EP-0568898-A1 Benzothiepine-, benzothiopyrane- and benzothiophenyle derivatives, their preparation and use as medicine F. HOFFMANN-LA ROCHE AG (CH) 1993-11-10 EP disclosed
US-5164387-A Antitumor agents, skin disorders, antiinflammatory agents HOFFMANN-LAROCHE INC. (US) 1992-11-17 US disclosed
US-5037825-A Useful In The Treatment Of Neoplasms, Dermatoses And Aging Of The Skin HOFFMANN-LA ROCHE INC. (US) 1991-08-06 US disclosed
EP-0350846-A2 Condensed heterocyclic compounds and their use in therapy F. HOFFMANN-LA ROCHE AG (CH) 1990-01-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230149414-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB KDM4E 1848/4885HTT 234/4885PARP10 400/4885
US-20150038438-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE MRPL21, SLC11A2, CLPP KDM4E 4305/4885HTT 4310/4885PARP10 2838/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.